Stiolto Respimat (tiotropium bromide/olodaterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). It comes with an inhaler for breathing the drug into your ...
Stiolto Respimat (tiotropium bromide and olodaterol) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD). Stiolto Respimat can cause side effects that range from mild to ...
RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) ...
FDA recently accepted sNDA filing to review data from DYNAGITO trial for inclusion in Stiolto Respimat label A COPD exacerbation, or a flare-up, is a sudden worsening of symptoms, such as increased ...
RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...
Boehringer Ingelheim announced new data from a Phase 3b study of Stiolto Respimat (tiotropium, olodaterol) in which treatment with Stiolto Respimat led to significant improvements in SGRQ total score ...
Tiotropium 2.5mcg, olodaterol 2.5mcg; per actuation; inhalation spray; contains benzalkonium chloride. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback